Xueping Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xueping Liu has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chengde Mao
Department of Chemistry, Purdue University, West Lafayette, IN, USA
1 shared publication - Guansong Wang
Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing, China
1 shared publication - Huaping Chen
Department of Radiology, Washington University School of Medicine, St. Louis, USA
1 shared publication - Ji-Gang Dai
Department of Thoracic Surgery, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, China
1 shared publication - Jianxiang Zhang
Department of Pharmaceutics College of Pharmacy Third Military Medical University (Army Medical University) Chongqing China
1 shared publication Pin Qian
Institute of Respiratory Diseases, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, China
1 shared publication
Latest Publications
- Open Access
- 1 June 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 4825-4837
Abietic acid suppresses non-small-cell lung cancer cell growth via blocking IKKβ/NF-κB signaling
Background: Abietic acid (AA) is one of the terpenoids, which are multifunctional natural compounds. It has been reported that AA possesses favorable therapeutic effects on inflammation and obesity. Method: In the present study, we determined the inhibitory effect of AA on the proliferation and growth of non-small-cell lung cancer (NSCLC) cell lines for the first time. Then, flow cytometry and Western blot analysis were applied to determine the cell apoptosis and cell cycle. Finally, surface plasmon resonance, molecular docking and molecular dynamics (MD) simulation were performed to explore the underlying molecular mechanisms. Results: In vitro experiments indicated that AA displays significant anti-proliferative, cell cycle arresting and pro-apoptotic activities. Mechanistically, AA abrogated tumor necrosis factor-α induced phosphorylation of IκB kinase (IKKα/β) (Ser176/180) and IkBα (Ser32), and inhibited the nuclear translocation of nuclear factor‐κB. Moreover, we found that the activities of AA against NSCLC cells were mediated by its IKKβ inhibition. Molecular docking and MD simulations demonstrated that the mechanism of action between AA and IKKβ was through hydrophobic interactions. Conclusion: Our data indicate that AA could be a promising lead compound for the discovery of novel IKKβ inhibitors and potential agents for the treatment of NSCLC.
- 1 June 2019
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 12, 4825-4837
Open AccessAbietic acid suppresses non-small-cell lung cancer cell growth via blocking IKKβ/NF-κB signaling
Background: Abietic acid (AA) is one of the terpenoids, which are multifunctional natural compounds. It has been reported that AA possesses favorable therapeutic effects on inflammation and obesity. Method: In the present study, we determined the inhibitory effect of AA on the proliferation and growth of non-small-cell lung cancer (NSCLC) cell lines for the first time. Then, flow cytometry and Western blot analysis were applied to determine the cell apoptosis and cell cycle. Finally, surface plasmon resonance, molecular docking and molecular dynamics (MD) simulation were performed to explore the underlying molecular mechanisms. Results: In vitro experiments indicated that AA displays significant anti-proliferative, cell cycle arresting and pro-apoptotic activities. Mechanistically, AA abrogated tumor necrosis factor-α induced phosphorylation of IκB kinase (IKKα/β) (Ser176/180) and IkBα (Ser32), and inhibited the nuclear translocation of nuclear factor‐κB. Moreover, we found that the activities of AA against NSCLC cells were mediated by its IKKβ inhibition. Molecular docking and MD simulations demonstrated that the mechanism of action between AA and IKKβ was through hydrophobic interactions. Conclusion: Our data indicate that AA could be a promising lead compound for the discovery of novel IKKβ inhibitors and potential agents for the treatment of NSCLC.
- 1 May 2014
- Published by Elsevier in Biomaterials
- Vol. 35 (14) , 4401-4416
Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector
- 1 May 2014
- Published by Elsevier in Biomaterials
- Vol. 35 (14) , 4401-4416
Inhibition of hypoxia-induced proliferation of pulmonary arterial smooth muscle cells by a mTOR siRNA-loaded cyclodextrin nanovector